Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of AGP100 (DNS-6288) in catecholaminergic polymorphic ventricular tachycardia
2025-521611-39-00Phase 2Authorised
- Sponsor
- Agiana Pharmaceuticals
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of AGP100 in catecholaminergic polymorphic ventricular tachycardia (CPVT), sponsored by Agiana Pharmaceuticals. Primary endpoints: Safety and Tolerability. Planned start Dec 2025; status: authorised.
02
Drugs
AGP100
03
Conditions
catecholaminergic polymorphic ventricular tachycardia (CPVT)
Beyond the preview
Go deeper on 2025-521611-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521611-39-00.